# US 2019/0315880 A1 · Human antibody drug conjugates against tissue factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315880 A1
- Document ID: US20190315880A1
- Status: Published application
- Kind: A1
- Application number: 16/367,933
- Filed: 2019-03-28
- Published: 2019-10-17
- Earliest claimed: 2010-06-15
- Assignees: Genmab A/S
- Applicants: Genmab A/S
- Inventors: David SATIJN; Sandra VERPLOEGEN; Wim BLEEKER; Steen LISBY; Jan VAN DE WINKEL; Patrick VAN BERKEL; Paul PARREN
- Web page: https://patentgrep.com/patent/US20190315880A1

## CPC

- C07K 16/30: from tumour cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6817: {Toxins}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/36: against blood coagulation factors
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A method of producing an antibody drug conjugate which binds to tissue factor (TF), the method comprising
(a) providing an antibody which binds to TF, wherein the antibody comprises:
(i) a VH region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:6, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 7, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 8, and a VL region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:46, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 47, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 48,
(ii) a VH region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:34, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 35, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 36, and a VL region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:74, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 75, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 76,
(iii) a VH region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:38, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 39, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 40, and a VL region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:78, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 79, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 80, or
(iv) a VH region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO:2, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 3, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 4, and a VL region comprising a CDR1 region having the amino acid sequence set forth in SEQ ID NO: 42, a CDR2 region having the amino acid sequence set forth in SEQ ID NO: 43, and a CDR3 region having the amino acid sequence set forth in SEQ ID NO: 44;
(b) mixing the antibody with a drug under conditions that promote formation of the antibody drug conjugate; and
(c) isolating the antibody drug conjugate from unconjugated antibody and unconjugated drug.

### Claim 28 (depends on 27)

The method of claim 27, wherein the antibody comprises:
(i) a VH region comprising an amino acid sequence of SEQ ID NO: 5 and a VL region comprising an amino acid sequence of SEQ ID NO: 45,
(ii) a VH region comprising an amino acid sequence of SEQ ID NO: 33 and a VL region comprising an amino acid sequence of SEQ ID NO: 73,
(iii) a VH region comprising an amino acid sequence of SEQ ID NO: 37 and a VL region comprising an amino acid sequence of SEQ ID NO: 77, or
(iv) a VH region comprising an amino acid sequence of SEQ ID NO: 1 and a VL region comprising an amino acid sequence of SEQ ID NO: 41.

### Claim 29 (depends on 27)

The method of claim 27, wherein the antibody is a full length antibody.

### Claim 30 (depends on 27)

The method of claim 27, wherein the antibody is a human monoclonal IgG1 antibody.

### Claim 31 (depends on 27)

The method of claim 27, wherein the drug is selected from the group consisting of a cytotoxin, a chemotherapeutic drug, a cytokine, an immunosuppressant, or a radioisotype.

### Claim 32 (depends on 27)

The method of claim 27, wherein the drug is an auristatin, or a functional peptide analog or derivative thereof.

### Claim 33 (depends on 32)

The method of claim 32, wherein the auristatin is monomethyl auristatin E (MMAE):

### Claim 34 (depends on 32)

The method of claim 32, wherein the auristatin is monomethyl auristatin F (MMAF):

### Claim 35 (depends on 27)

The method of claim 27, wherein the drug is conjugated to the antibody at internal residues or sugars.

### Claim 36 (depends on 27)

The method of claim 27, wherein the drug is conjugated to the antibody via a linker.

### Claim 37 (depends on 36)

The method of claim 36, wherein the linker is attached to sulphydryl residues of the antibody obtained by partial reduction of the antibody.

### Claim 38 (depends on 36)

The method of claim 36, wherein the linker is an uncleavable linker.

### Claim 39 (depends on 36)

The method of claim 36, wherein the linker is a cleavable linker.

### Claim 40 (depends on 36)

The method of claim 36, wherein the linker is a peptidyl linker.

### Claim 41 (depends on 40)

The method of claim 40, wherein the peptidyl linker is at least two amino acids long.

### Claim 42 (depends on 41)

The method of claim 41, wherein the linker is a Val-Cit (vc) linker or a Phe-Lys linker.

### Claim 43 (depends on 36)

The method of claim 36, wherein the linker-drug is vcMMAF or vcMMAE:
wherein p denotes a number of from 1 to 8, S represents a sulphydryl residue of the antibody, and Ab designates the antibody.

### Claim 44 (depends on 43)

The method of claim 43, wherein p is 4.

### Claim 45 (depends on 36)

The method of claim 36, wherein the linker-drug is mcMMAF:
wherein p denotes a number of from 1 to 8, S represents a sulphydryl residue of the antibody, and Ab designates the antibody.

### Claim 46 (depends on 45)

The method of claim 45, wherein p is 4.
